CANDEL THERAPEUTICS, INC. CADL 深 滬
等待開盤 08-21 09:30:00 美东时间
5.56
0.000
0.00%
華盛通- 最 高5.64
- 今 開5.56
- 成交量 73.97万股
- 最 低 5.45
- 昨 收 5.56
- 總市值 3.05亿
- 52周最高 14.60
- 市盈率 靜 --
- 換手率 1.35%
- 52周最低 3.785
- 委 比 52.74%
- 總股本 5489.51万
- 歷史最高 14.78
- 量 比 0.87
- 振 幅 3.42%
- 歷史最低 0.66
- 每 手 1
- 風險率 3.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Candel Therapeutics Advances with Promising Cancer Therapies
Candel Therapeutics, Inc. ( ($CADL) ) has released its Q2 earnings. Here is a b...
08-19 12:09
Candel Therapeutics Q2 EPS $(0.09) Beats $(0.17) Estimate
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.17) by 46.43 percent. This is a 87.84 percent increase over losses of $(0.74) per share
08-14 20:29
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Candel Therapeutics announced positive results from its phase 3 clinical trial of CAN-2409 in prostate cancer and received FDA's RMAT designation. The company also reported financials with $100.7 million in cash, tracking toward a Q4 2026 BLA submission. CAN-2409 showed promising outcomes in prostate, pancreatic, and lung cancers, with extended survival rates. Candel appointed new leadership and completed a registered direct offering to support p...
08-14 12:05
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
Candel Therapeutics的CEO Paul Peter Tak将在Canaccord Genuity的会议上发言，探讨其多模式生物免疫疗法在癌症治疗中的进展。Candel专注于开发基于腺病毒和HSV的免疫疗法，其主要产品CAN-2409在前列腺癌和肺癌等适应症中取得进展，并获得FDA的RMAT和Fast Track认定。CAN-3110则针对脑瘤，正处于临床试验阶段。会议将于8月13日线上直播。
07-30 12:05
Candel Therapeutics Secures EMA Orphan Designation For CAN-2409 For Treatment Of Pancreatic Cancer
andel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that
07-24 20:07
ASML, J B Hunt Transport And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the S&P 500 futur...
07-16 20:28
Candel Therapeutics Added To Multiple Russell Value Indexes In 2025 Reconstitution
Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that
07-09 20:09
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
Candel Therapeutics was added to multiple Russell Value® indexes as part of the 2025 Russell US Indexes annual reconstitution, reflecting significant progress in advancing its clinical programs focused on cancer immunotherapies. The Company was included in the Russell 2500 Value®, Russell Small Cap Value®, Russell 2000 Value®, Russell Microcap Value®, and Russell 3000E® Value Indexes, while retaining its membership in the Russell 3000® Index. CEO...
07-09 12:05
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
07-01 09:24
